technology
Cell therapy
Therapeutic use of living cells (T, NK, TIL) to treat disease, including CAR-T, CAR-NK, TIL and allogeneic platforms.
Where it's used
NK-cell & CAR-NK therapy
CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform.
Personalized & regenerative medicine
Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.
TIL therapy (tumor-infiltrating lymphocytes)
TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a breakthrough in metastatic melanoma.